Cagrilintide

Cagrilintide, a long-acting amylin analog, is being studied for obesity and type 2 diabetes. Here are its potential benefits based on clinical research:

1.  Weight Loss: Cagrilintide promotes significant weight reduction by enhancing satiety, slowing gastric emptying, and reducing appetite. In phase 2 trials, it achieved 6-10.8% body weight loss over 26 weeks at doses of 0.3-4.5 mg weekly. Some studies suggest potential for up to 25% weight loss.

2.  Improved Blood Sugar Control: For type 2 diabetes, cagrilintide improves glycemic control by modulating postprandial glucose spikes.

3.  Cardiometabolic Health: Weight loss from cagrilintide is linked to better metabolic markers, like improved cholesterol, blood pressure, and insulin resistance. It may reduce risks of heart disease, stroke, and diabetes-related complications. Preclinical studies also suggest benefits for liver health (e.g., alcohol-related liver disease) and cardiovascular function.

4.  Enhanced Satiety and Reduced Cravings: By acting on the brain’s hunger centers (homeostatic and hedonic regions), cagrilintide increases feelings of fullness and may dampen emotional eating. Users report less “food noise” and fewer cravings, supporting sustained weight management.

5.  Convenient Dosing: As a once-weekly injection.